Venkataraman Rohini, Yusuf Kamran
Section of Neonatology, University of Calgary, Calgary, AB, Canada.
J Neonatal Perinatal Med. 2017;10(3):329-332. doi: 10.3233/NPM-16131.
Hemolytic disease of newborn (HDN) is a condition that develops in a fetus, when the IgG molecules produced by the mother pass through the placenta and attack the fetal red blood cells. HDN can occur due to Rh and ABO incompatibilities between the mother and the fetus as well as due to other allo-immune antibodies belonging to Kell (K and k), Duffy (Fya), Kidd (Jka and Jkb), and MNS (M, N, S, and s) systems. Role of intravenous immunoglobulin in management of HDN is not clear.SARA red blood cell antigen, first discovered in 1990 is a low frequency antigen. We report, a multiparous female whose pregnancy was complicated by HDN due to anti-SARA antibodies requiring both exchange transfusion and intravenous immunoglobulin. The response was sustained after intravenous immunoglobulin (IVIG) rather than after exchange transfusion.
新生儿溶血病(HDN)是一种发生于胎儿的病症,当母亲产生的IgG分子穿过胎盘并攻击胎儿红细胞时就会出现这种情况。HDN可能由于母亲与胎儿之间的Rh和ABO血型不相容以及属于凯尔(K和k)、达菲(Fya)、基德(Jka和Jkb)和MNS(M、N、S和s)系统的其他同种免疫抗体而发生。静脉注射免疫球蛋白在HDN治疗中的作用尚不清楚。SARA红细胞抗原于1990年首次发现,是一种低频抗原。我们报告了一位经产妇,其妊娠因抗SARA抗体导致HDN并发症,需要进行换血输血和静脉注射免疫球蛋白治疗。静脉注射免疫球蛋白(IVIG)治疗后的反应持续存在,而非换血输血后。